Latest Share Chat

Avacta Group Share News (AVCT)

Avacta Group Information

Buy AVCT Shares
Add AVCT to Watchlist
Add AVCT to Alert

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 45.75

Bid: 45.50

Ask: 46.00

Change: 1.00 (2.19%)

Spread: 0.50 (1.099%)

Open: 45.00

High: 46.75

Low: 44.25

Prev. Close: 45.75

Last checked at -

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Thu, 01st Oct 2020 06:40

Avacta Group PLC - Wetherby, England-based pre-clinical stage biotechnology company - Launches bead-assisted mass spectrometry, or BAMS, SARS-CoV-2 virus test. "The BAMS assay uses the Affimer reagents specific to the SARS-CoV-2 virus to capture the virus spike protein from the sample for rapid detection by mass spectrometry, using the installed base of these instruments in hospitals," Avacta says. Adds that one thousand samples per day can be analysed by a single technician using BAMS.

Current stock price: 155.00 pence, up 11% on Wednesday.

Year-to-date change: up sharply from 17.25p

By Eric Cunha; ericcunha@alliancenews.com

More News

1 Jun 2021 11:16

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

28 May 2021 11:29

Avacta still waiting on response from UK regulator over Covid test

28 May 2021 07:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

10 May 2021 11:13

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

22 Apr 2021 12:17

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

20 Apr 2021 15:18

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

20 Apr 2021 12:17

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

20 Apr 2021 11:35

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

15 Apr 2021 14:56

UK earnings, trading statements calendar - next 7 days

6 Apr 2021 13:53

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

6 Apr 2021 11:03

Avacta signs global distribution deal with Abcam

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.

25 Mar 2021 15:57

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

9 Mar 2021 20:19

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

9 Mar 2021 11:08

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

8 Mar 2021 19:07

Latest Share Chat

Avacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Login to your account

Quickpicks are a member only feature

Login to your account